Indivior Inc. v. Dr. Reddy's Laboratories, S.A. (Fed. Cir. 2018)

McDonnell Boehnen Hulbert & Berghoff LLP

Having a court grant a preliminary injunction is frequently an important strategic victory for a patent plaintiff in an infringement suit.  The injunction not only eliminates a revenue stream for the accused infringer but also imposes other requirements (such as burdensome efforts to remove the alleged infringing article from the stream of commerce) that can (and indeed, are intended to) pressure the defendant to consider settlement.  But in order for a plaintiff to obtain an injunction, she must show a likelihood of prevailing on the merits, and in Indivior Inc. v. Dr. Reddy's Laboratories, S.A., the Federal Circuit recently found the District Court erred in finding such a likelihood, based on the patentee having disclaimed embodiments that encompassed the accused infringing article.

The case arose in ANDA litigation over Indivior's suboxone film product Suboxone®, a rapidly dissolving film formulation of two active ingredients:  buprenorphine, which decreases a patient's need for opioids, and naloxone, which deters abuse; it is the leading treatment for opioid dependency according to the Federal Circuit opinion.  The challenge for such formulations is drug content uniformity, i.e., having the ingredients homogeneously distributed in the films, which are produced from larger sheets that are cut into individual dosage units based on a particular size and shape to provide the appropriate dose of each drug.  U.S. Patent Nos. 9,931,305 and 8,603,514 (which have identical specifications) cover Indivior's product (the '305 patent being the only patent at issue in the case), which disclose methods for mixing the drugs with a polymer, casting the mixture to produce a wet film, and then "controllably drying the film to produce a solid sheet having less than ten percent variance in active ingredient throughout any given area."  Relevant to the issues before the Court, prior art methods (involving drying the films by applying warm air to only the top surface) were inadequate to achieve content uniformity, with films produced in this manner having a "rippled" surface.  The invention overcame these limitations by "applying heat to the bottom of the film, introducing controlled microwaves, controlling the air flow above and beneath the film, and employing furnace filters."

The parties had engaged in ANDA litigation involving the '514 patent brought in the District of Delaware; claim 62 of this patent in informative:

62.  A drug delivery composition comprising:
    (i) a cast film comprising a flowable water-soluble or water swellable film-forming matrix comprising one or more so substantially water soluble or water swellable polymers; and a desired amount of at least one active;
    wherein said matrix has a viscosity sufficient to aid in substantially maintaining non-self-aggregating uniformity of the active in the matrix;
    (ii) a particulate active substantially uniformly stationed in the matrix; and
    (iii) a taste-masking agent selected from the group consisting of flavors, sweeteners, flavor enhancers, and combinations thereof to provide taste- masking of the active;
    wherein the particulate active has a particle size of 200 microns or less and said flowable water-soluble or water swellable film-forming matrix is capable of being dried without loss of substantial uniformity in the stationing of said particulate active therein; and
    wherein the uniformity subsequent to casting and drying of the matrix is measured by substantially equally sized individual unit doses which do not vary by more than 10% of said desired amount of said at least one active.

The District Court held that Indivior had disclaimed (indeed, disparaged) conventional air drying methods in these claims, and on this basis construed "dried" (and "drying") to exclude embodiments that only used "conventional convection air drying from the top."  The District Court found that Dr. Reddy's did not infringe the claims of the '514 patent (a decision on appeal to the Federal Circuit).

Reacting to this decision, Indivior amended claims in a pending application that matured into the '305 patent that replaced "dried" and "drying" with "continuously" and "continuously cast," as illustrated in claim 26 of the '305 patent:

26.  A drug delivery composition comprising:
    (i) a continuously cast film produced on a manufacturing line comprising a flowable water-soluble or water swellable film-forming matrix comprising one or more substantially water soluble or water swellable polymers; and at least one active;
    wherein said matrix has a viscosity sufficient to aid in substantially maintaining non-self- aggregating uniformity of the active in the matrix;
    (ii) a particulate active substantially uniformly stationed in the matrix; and
    (iii) a taste-masking agent selected from the group consisting of flavors, sweeteners, flavor enhancers, and combinations thereof to provide taste- masking of the active;
    wherein the particulate active has a particle size of 200 microns or less and said flowable water-soluble or water swellable film-forming matrix is capable of being continuously cast on the manufacturing line without loss of substantial uniformity in the stationing of said particulate active therein; and
    wherein said uniformity of the continuously cast film is measured by substantially equally sized individual unit doses cut from the continuously cast film which do not vary by more than 10% of a desired amount of said at least one active.

Indivior brought this ANDA suit against Dr. Reddy's in New Jersey based on the '305 patent claims; nevertheless, Dr. Reddy's launched at risk after the FDA approved its ANDA.  Indivior petitioned the District Court for a temporary restraining order (TRO) and a preliminary injunction (PI), both of which were granted (the TRO after a telephone conference between the parties and the Court, and the PI after a hearing).  As part of the District Court's determinations in support of granting the PI, the Court held that Indivior was likely to succeed on the merits that Dr. Reddy's product infringed the '305 patent claims and that those claims were not invalid nor unenforceable.  In construing the scope of the asserted '305 patent claims, the New Jersey Court declined to apply the Delaware Court's reasoning that Indivior's specification disclaimed embodiments encompassing Dr. Reddy's product, based in part on the '305 patent claim not reciting a "drying" limitation.  This different construction also supported the New Jersey Court's decision that a PI (and Indivior's lawsuit) was not barred under the doctrine of claim preclusion.  This appeal followed.

The Federal Circuit reversed, in an opinion by Judge Stoll joined by Judge Lourie; Judge Newman filed a dissenting opinion.  The majority held that the District Court had abused its discretion in granting the PI, because in their view the '305 patent specification disclaimed conventional air-drying methods (such as those used by Dr. Reddy's) for producing such films.  This conclusion was supported by "remarks in the specification," specifically that such conventional methods did not solve the content uniformity problems in prior art drying methods.  Disclaimer (or, put another way, disavowal) requires that a specification be express ("make clear" that the inventor intends to disclaim part of the scope of a claim that would otherwise encompass certain embodiments based on the plain meaning of claim terms).  This must be more than merely expressing a patentee's preference with regard to certain features; characteristic of effective disclaimers are instances where "'the specification goes well beyond expressing the patentee's preference . . . [such that] its repeated derogatory statements about [a particular embodiment]," citing Openwave Sys., Inc. v. Apple Inc., 808 F.3d 509, 513 (Fed. Cir. 2015) (quoting Chicago Bd. Options Exch., Inc. v. Int'l Sec. Exch., LLC, 677 F.3d 1361, 1372 (Fed. Cir. 2012)).

In this case (and in direct analogy to the Openwave Systems caseand SciMed Life Sys., Inc. v. Advanced Cardiovascular Sys., Inc., 242 F.3d 1337, 1343–44 (Fed. Cir. 2001), "the '305 patent is 'rife with remarks that disparage, and therefore, disclaim' solely using conventional top air drying to form films," according to the majority opinion.  The opinion cited disclosure in the specification that "conventional drying methods themselves are unable to provide uniform films" and that such methods "produce a 'ripple effect' that results in 'an uneven, and therefore non-uniform film.'"  The opinion also cites two specific examples in the specification that illustrate the advantage of avoiding conventional top-only air drying in favor of the claimed methods that employed other drying geometries and methodologies; the opinion recites several portions of the specification to illustrate its points.

The majority rejected Indivior's argument that these statements in the specification were not relevant to construing the asserted '305 patent claims because these claims did not recite "drying" or "dried."  The majority held that the substitute language, "continuously cast film," implicated the disclaimer of conventional drying because drying was part of the disclosed methods for producing a continuously cast film.  And the opinion states that "[t]he specification makes clear that a film produced using only conventional top air drying cannot satisfy the claim limitations."

The majority also rejected Indivior's argument that "it is improper to import drying, a process limitation, into the '305 patent's composition claims because there is an absence of 'specific process language.'"  While acknowledging that "[a]s a general rule, product claims are not limited to the method of manufacture disclosed in the specification," citing Vanguard Prod. Corp. v. Parker Hannifin Corp., 234 F.3d 1370, 1372 (Fed. Cir. 2000), "process steps can be treated as part of a product claim if the patentee has made clear that the process steps are an essential part of the claimed invention," citing Andersen Corp. v. Fiber Composites, LLC, 474 F.3d 1361, 1375 (Fed. Cir. 2007).  That is the case here, in the majority's opinion, because a "continuously cast film" requires a process for achieving the end product.  The '305 patent discloses only an irrelevant extrusion method and a wet casting method, the product of which must be dried ("combining a polymer and a polar solvent, forming the combination into a film, and drying the film in a controlled manner").  Analogous to the Anderson case, the majority found that "Indivior's patent specification makes clear that the drying process is an essential part of the '305 claimed invention" in order to achieve content uniformity, which an expressly recited limitation in the '305 patent claims.

In addition, the majority found that Indivior was barred by the claim preclusion doctrine because the '305 patent claims were patentably indistinct from the '514 patent claims held before the Delaware District Court not to be infringed by Dr. Reddy's products (a decision that follows inexorably from the majority's holding that replacing "dried" and "drying" with "continuously cast" did not distinguish the claims of the '305 patent from the earlier-asserted claims of the '514 patent).  Finally, the majority held that Indivior's filing a terminal disclaimer provided a "strong clue" that these claims were not patentably distinct.

Judge Newman dissented.  In her opinion, the factors surrounding the District Court's grant of the PI (that "Dr. Reddy's Laboratories[] could readily be made whole by monetary payment if the injunction was imposed in error," that "Indivior could not recover its reputation and market share if the injunction was erroneously denied," and that Indivior had posted a $72 million bond protecting Dr. Reddy's from any adverse monetary consequences) were sufficient for the Court not to disturb the District Court's determination.  Judge Newman's opinion is based on the equitable nature of grant of a preliminary injunction, which requires appellate review on the propriety of a District Court's equitable discretion.  Here, Judge Newman chided her brethren for focusing on the substantive merits of Indivior's patent infringement allegations, supported by a decision of a different district court, "on a different patent with different claims" (and that is on appeal to the Federal Circuit), rather than on the equitable considerations in the case.

Judge Newman was also not persuaded on the question of whether there was specification disclaimer.  In her view, the majority improperly imported a process limitation into a claim for a formulation:

My colleagues select the drying method claimed in a different patent (the '514 parent patent) and place that limitation in the claims of the '305 patent, although the patentee expressly amended the '305 claims to remove the drying method.  My colleagues give the amended '305 claims identical scope to the claims of the '514 patent, the patent previously litigated in Delaware.  My colleagues then conclude that the '305 claims would have the same infringement position as the '514 claims were found to have in Delaware.  This is improper.  It is improper for a court to rewrite a product claim to contain a process limitation from the specification—here contained in a preferred but not sole embodiment—for it confounds the roles of the specification and the claims.  See Raytheon, 724 F.2d at 957.  "[I]f we once begin to include elements not mentioned in the claim, in order to limit such claim . . . , we should never know where to stop."  Phillips, 415 F.3d at 1312 (omission in original) (quoting McCarty v. Lehigh Valley R.R. Co., 160 U.S. 110, 116 (1895)) [citation to the record omitted].

Judge Newman saw nothing improper in the amendments to the claims that ultimately granted as the '305 patent, replacing "dried" and "drying" with "continuously" and "continuously cast."  To her, these amendments broadened the scope of the claim so as not to be limited to any particular film-casting (or drying) method.

Finally, Judge Newman disagreed with the majority on the issue of claim preclusion.  Citing precedent, she contended that it is improper to infer an admission from an applicant filing a terminal disclaimer; see, Ventana Medical Systems, Inc. v. Biogenex Laboratories, Inc., 473 F.3d 1173, 1184 n.4 (Fed. Cir. 2006).  Moreover, the status of the Delaware District Court's decision (being on appeal), raises the specter of the Court deciding Indivior's suit should be dismissed on issue preclusion grounds over a decision that might itself be overturned, citing Butler v. Eaton, 141 U.S. 240, 242–44 (1891), Levi Strauss & Co. v. Abercrombie & Fitch Trading Co., 719 F.3d 1367, 1372 (Fed. Cir. 2013), and 18A Charles A. Wright, et al., Federal Practice and Procedure § 4433 (2d ed. 2002).

Finally, Judge Newman objected to the majority's refusal to consider the District Court's reasoning on the other equitable factors involved in a preliminary injunction determination:

It is well settled that the granting of a temporary injunction, pending final hearing, is within the sound discretion of the trial court; and that, upon appeal, an order granting such an injunction will not be disturbed unless contrary to some rule of equity, or the result of improvident exercise of judicial discretion [citing Deckert v. Independence Shares Corp., 311 U.S. 282, 290 (1940)].

Indivior Inc. v. Dr. Reddy's Laboratories, S.A. (Fed. Cir. 2018)
Nonprecedential disposition
Panel: Circuit Judges Newman, Lourie, and Stoll
Opinion by Circuit Judge Stoll; dissenting opinion by Circuit Judge Newman

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Written by:

McDonnell Boehnen Hulbert & Berghoff LLP

McDonnell Boehnen Hulbert & Berghoff LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at:

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit
  • New Relic - For more information on New Relic cookies, please visit
  • Google Analytics - For more information on Google Analytics cookies, visit To opt-out of being tracked by Google Analytics across all websites visit This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at:

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.